ReviewNature reviews. Disease primers2020
Hypersensitivity pneumonitis.
Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 151 citations in OpenAlex.
- [Hypersensitivity pneumonitis : S2K guideline from a radiological perspective].Radiologie (Heidelberg, Germany) · 2025Guideline
- Diagnosis and Treatment of Hypersensitivity Pneumonitis: S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology.Respiration; international review of thoracic diseases · 2025Guideline
- Study of nasal mucosa histopathological changes in patients with hypersensitivity pneumonitis.Scientific reports · 2023Trial
- The Therapeutic Efficacy of Inhaled Vitamin D3 Metabolites Initiated During the Acute Phase of Hypersensitivity Pneumonitis: An In Vivo Study.Molecules (Basel, Switzerland) · 2026Article
- How experimental models have unlocked hidden mechanisms of hypersensitivity pneumonitis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Lung fibroblasts contribute to release of serum amyloid A as potential biomarker of exacerbation of lung fibrosis in mice.ERJ open research · 2026Article
- Humidifier lung and summer-type hypersensitivity pneumonitis in Japan: a nationwide retrospective observational study of clinical, radiological and pathological features.BMJ open respiratory research · 2026Observational
- Current concepts in the diagnosis and treatment of hypersensitivity pneumonitis: a narrative review.Respiratory research & clinical practice · 2026Review
- Mechanisms of exercise limitation and prevalence of pulmonary hypertension in hypersensitivity pneumonitis.ERJ open research · 2026Article
- A novel agarose-free, standardized generation and versatile ECM characterization of decellularized scaffolds from normal and fibrotic human lung tissue.Frontiers in bioengineering and biotechnology · 2026Article
- "Look What the Cat Dragged In": Delayed-Onset Hypersensitivity Pneumonitis Due to Pregnancy.Cureus · 2025Article
- Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease.Scientific reports · 2025Article
- Summer-type hypersensitivity pneumonitis.Internal and emergency medicine · 2025Article
- Expert consensus on cancer treatment-related lung injury.Journal of thoracic disease · 2025Review
- Pathogenic TNFRSF13B Variant in an Adult Japanese Patient with Common Variable Immunodeficiency.Internal medicine (Tokyo, Japan) · 2025Article
- Immunopathological characteristics and therapeutic effects of UC-MSCs in a pigeon breeder's lung mouse model.Acta biochimica et biophysica Sinica · 2025Article
- Importance of early detection and treatment of occupational hypersensitivity pneumonitis.Journal of occupational health · 2025Review
- Concomitant diagnosis of hypersensitivity pneumonitis and localized epithelioid mesothelioma: a rare case report.Einstein (Sao Paulo, Brazil) · 2025Article
- Correlation of Environmental Aerosols and Changes in Pulmonary Function of Pigeon Breeders in Turpan.International journal of general medicine · 2025Article
- Climate change, air pollution and chronic respiratory diseases: understanding risk factors and the need for adaptive strategies.Environmental health and preventive medicine · 2025Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity pneumonitis (HP) is a complex syndrome caused by the inhalation of a variety of antigens in susceptible and sensitized individuals. These antigens are found in the environment, mostly derived from bird proteins and fungi. The prevalence and incidence of HP vary widely depending on the intensity of exposure, the geographical area and the local climate. Immunopathologically, HP is characterized by an exaggerated humoral and cellular immune response affecting the small airways and lung parenchyma. A complex interplay of genetic, host and environmental factors underlies the development and progression of HP. HP can be classified into acute, chronic non-fibrotic and chronic fibrotic forms. Acute HP results from intermittent, high-level exposure to the inducing antigen, usually within a few hours of exposure, whereas chronic HP mostly originates from long-term, low-level exposure (usually to birds or moulds in the home), is not easy to define in terms of time, and may occur within weeks, months or even years of exposure. Some patients with fibrotic HP may evolve to a progressive phenotype, even with complete exposure avoidance. Diagnosis is based on an accurate exposure history, clinical presentation, characteristic high-resolution CT findings, specific IgG antibodies to the offending antigen, bronchoalveolar lavage and pathological features. Complete antigen avoidance is the mainstay of treatment. The pharmacotherapy of chronic HP consists of immunosuppressive drugs such as corticosteroids, with antifibrotic therapy being a potential therapy for patients with progressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.